PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/12, 15/62, C07K 14/705, 16/28, C12N 15/70

A2

(11) International Publication Number: WO 98/50547

(43) International Publication Date: 12 November 1998 (12.11.98)

(21) International Application Number: PCT/US98/08979

(22) International Filing Date: 7 May 1998 (07.05.98)

(30) Priority Data:

60/044,293	7 May 1997 (07.05.97)	US
60/072,212	22 January 1998 (22.01.98)	US
60/076,947	5 March 1998 (05.03.98)	US

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(72) Inventors: HARDIMAN, Gerard, T.; 4 Howe Street, Watertown, MA 02172 (US). ROCK, Fernando, L.; 721 Shell Boulevard #203, Foster City, CA 94404 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US).

(74) Agents: McLAUGHLIN, Jaye, P. et al.; Schering–Plough Corporation, Patent Dept. K–6–1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033–0530 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: HUMAN TOLL–LIKE RECEPTOR PROTEINS, RELATED REAGENTS AND METHODS

(57) Abstract

Nucleic acids encoding nine human receptors, designated DNAX Toll–like receptors 2–10 (DTLR2–10), homologous to the Drosophila Toll receptor and the human IL–1 receptor, purified DTLR proteins and fragments thereof, mono–/polyclonal antibodies against these receptors, and methods for diagnostic and therapeutic use.

